New nasal treatment for Alzheimer's disease using allopregnanolone
Novel Intranasal Formulations of Allopregnanolone, a Regenerative Therapeutic for Alzheimer's Disease
This study is testing a new way to deliver a medication called allopregnanolone through the nose to help make it easier for older adults with Alzheimer's disease to take their treatment and feel better.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Neutherapeutics, LLC NIH-funded |
| Lab location | 1 site (Tucson, United States) |
| Project ID | NIH-10698555 on NIH RePORTER |
What this research studies
This research focuses on developing a new formulation of allopregnanolone, a neurosteroid, to treat Alzheimer's disease (AD) through an intranasal delivery method. The goal is to create a treatment that is easier for patients to use, especially for older adults who may struggle with other forms of medication administration. The study builds on previous safety trials and aims to address challenges related to long-term use and patient compliance. By optimizing the delivery method, the research seeks to enhance the therapeutic effects of allopregnanolone in managing AD symptoms.
Who could benefit from this research
Good fit: Ideal candidates for this research are older adults diagnosed with Alzheimer's disease who may benefit from new treatment options.
Not a fit: Patients with early-stage Alzheimer's or those not diagnosed with Alzheimer's disease may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a more effective and user-friendly treatment option for patients with Alzheimer's disease.
How similar studies have performed: While the use of allopregnanolone has shown promise in previous studies, this specific intranasal formulation is a novel approach that has not been extensively tested.
Where this research is happening
Tucson, United States
- Neutherapeutics, LLC — Tucson, United States (Active)
Researchers
- Principal investigator: Rinehart, John — Neutherapeutics, LLC
- Study coordinator: Rinehart, John
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.